ストックスクリーナーアプリを入手
2.44
1.24%
0.03
アフターアワーズ：
2.40
-0.04
-1.64%
前日終値:
$2.41
開ける：
$2.42
24時間の取引高:
119.86K
Relative Volume:
0.65
時価総額：
$7.38M
収益：
-
当期純損益:
$-31.88M
株価収益率:
-3.2533
EPS:
-0.75
ネットキャッシュフロー:
$-25.20M
1週間 パフォーマンス:
+12.44%
1か月 パフォーマンス:
+11.93%
6か月 パフォーマンス:
-70.42%
1年 パフォーマンス:
-89.99%
1日の値動き範囲:
$2.30
$2.46
1週間の範囲:
$2.17
$2.49
52週間の値動き範囲:
$2.05
$26.76
In 8 Bio Inc Stock (INAB) Company Profile
INAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
2.44 | 8.30M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-18 | 開始されました | Laidlaw | Buy |
| 2022-08-30 | 開始されました | H.C. Wainwright | Buy |
In 8 Bio Inc (INAB) 最新ニュース
Moving Average Trends for 2seventy bio Inc. Stock: What They IndicateFree Professional Trading Signals - Newser
Annovis Bio Inc. Stock Analysis and ForecastFree Predictions - PrintWeekIndia
Will Passage Bio Inc. stock benefit from interest rate changesAccelerated earnings growth - jammulinksnews.com
Layoff Tracker: Flagship Unicorns Tessera, Generate:Biomedicines Downsize - BioSpace
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference - Stock Titan
Tourmaline Bio Inc. Stock Analysis and ForecastHigh-yield market plays - jammulinksnews.com
Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire
What analysts say about 2seventy bio Inc. stockExceptional return forecasts - Autocar Professional
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - The Globe and Mail
What drives Mustang Bio Inc. stock priceMarket-leading growth rates - jammulinksnews.com
What analysts say about TELA Bio Inc. stockBreakout stock performance - Jammu Links News
Upstream Bio, Inc. shares fall 4.98% premarket after HBM Healthcare Investments reports an 8.4% decline in NAV per share. - AInvest
What drives Boundless Bio Inc. stock pricePowerful profit generation - jammulinksnews.com
Gossamer Bio Inc. Stock Analysis and ForecastMarket-leading capital gains - jammulinksnews.com
Why Climb Bio Inc. stock attracts strong analyst attentionEntry Level Low Risk Picks - Newser
Why Kronos Bio Inc. stock attracts strong analyst attentionFree Stock Investment Discussion Area - Newser
Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors - GlobeNewswire
Pre-market Movers: CLDI, BMGL, PROK, RXST... - RTTNews
KALA BIO Announces Completion of Enrollment in CHASE - GlobeNewswire
Cizzle Bio Submits NIH Grant Proposal with Premier Research Institutions to Advance Biomarker Blood Test for Lung Cancer - Yahoo Finance
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma - Yahoo Finance
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to - GlobeNewswire
Clinical-Stage Biotech INmune Bio Secures $19M Through Strategic Share Offering - Stock Titan
Breakthrough: New Alzheimer's Drug XPro Shows Promise in Key Patient Group, Zero ARIA Cases - Stock Titan
INMB SEC FilingsInmune Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Clinical-Stage Immunology Company INmune Bio Secures $19M from Healthcare Investors at Market Price - Stock Titan
Major Alzheimer's Treatment Milestone: INmune Bio Reveals Phase 2 Trial Results Next Week - Stock Titan
BioCryst's ORLADEYO Pediatric HAE Review Extended by FDA to December 2025 | BCRX SEC FilingForm 8-K - Stock Titan
Breakthrough in Dementia Treatment: Gene Therapy Maintains 18-Month Efficacy with Lower Dose Success - Stock Titan
ANVS gains NYSE approval of compliance plan, delisting risk eased | ANVS SEC FilingForm 8-K - Stock Titan
Global Protein Expression Market to Observe Growth at a CAGR of ~8% by 2032 | DelveInsight - GlobeNewswire
Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements (NYSE:NUVB) - Seeking Alpha
U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer - Quantisnow
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress - Yahoo Finance
Breakthrough: New Drug Reduces Alzheimer's Risk After Brain Injury, DoD-Backed Study Shows - Stock Titan
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial - GlobeNewswire Inc.
European Launch: TELA Bio's Natural Hernia Repair Device Shows 98.8% Success Rate - Stock Titan
TELA Bio Appoints Jeffrey Blizard as President - GlobeNewswire
Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews
KALA BIO to Present at Jefferies Global Healthcare Conference - GlobeNewswire
Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) Price Target at $20.33 - MarketBeat
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis - GlobeNewswire
Global Immunoprecipitation Market Set to Grow at a CAGR of 6-8%: Key Drivers and Challenges by 2029 - PharmiWeb.com
DNA Polymerase Market to Grow at 6–8% CAGR Driven by Genomics, PCR, and CRISPR Technologies by 2029 - PharmiWeb.com
GRI Bio Presents Positive Pre-Clinical Data Demonstrating - GlobeNewswire
Caisse Française de Financement Local: EMTN 2025-8 SOCIAL - The Manila Times
Protagenic Therapeutics Completes Acquisition of Phytanix Bio - TipRanks
Dimensional Fund Advisors LP Sells 592,968 Shares of bluebird bio, Inc. (NASDAQ:BLUE) - Defense World
GRI Bio CEO Reveals Latest Developments in Revolutionary NKT Cell Technology at Major Healthcare Conference - Stock Titan
In 8 Bio Inc (INAB) 財務データ
収益
当期純利益
現金流量
EPS
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):